Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 10 clinical trials
MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO) (MATAO)

The purpose of this study is to evaluate the efficacy of addition of letrozole to the standard maintenance therapy in subjects following a primary diagnosis of Estrogen-receptor (ER) positive high and low grade epithelial ovarian cancer (including fallopian tube and primary peritoneal cancer) and subsequent primary treatment surgery and chemotherapy. …

tumor debulking
cancer chemotherapy
ovarian cancer
ovarian epithelial carcinoma
  • 23 Mar, 2022
  • 15 locations
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

This phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial enrolls participants for …

undifferentiated carcinoma
cancer other
estimated creatinine clearance
bilateral oophorectomy
  • 11 May, 2022
  • 767 locations
Transvaginal Ultrasonography as a Screening Method for Ovarian Cancer

This is a large, prospective, single-arm cohort study of transvaginal ultrasonographic screening for ovarian cancer in intermediate to high-risk women from Kentucky. Detection of ovarian malignancy often occurs subsequent to the initial transvaginal sonography (TVS) screen therefore, it is important to offer continued screening to study participants based on our …

breast cancer
cancer of the ovary
  • 27 Jul, 2021
  • 1 location
Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers

Phase 1 trial to study the safety, pharmacokinetics and preliminary efficacy of STRO-002 given intravenously every 3 weeks.

measurable disease
undifferentiated carcinoma
fallopian tube
endometrial carcinoma
cancer chemotherapy
  • 02 Feb, 2022
  • 26 locations
Stereotactic Pelvic Adjuvant Radiation Therapy in Cancers of the Uterus.

Advanced technology has enabled radiation oncologists to more accurately and precisely target radiation to areas at risk while maximally sparing healthy tissue. Furthermore, there is growing evidence demonstrating both safety and efficacy for SBRT. We propose that these advantages are translatable to the adjuvant treatment of endometrial cancer. We submit …

cancer chemotherapy
systemic therapy
  • 26 Jan, 2021
  • 1 location
Phase I Trial of Defatcinib and VS-6766. (FRAME)

This is a multi-centre, investigator-initiated, dose escalation, Phase I trial of the combination of the FAK inhibitor, Defactinib (VS-6063), and the dual RAF/MEK inhibitor, VS-6766 (RO5126766) in patients with advanced solid tumours. VS-6766 (RO5126766) is the same compound as CH5126766. There are two parts to this study, the dose escalation …

measurable disease
lung cancer
serum bilirubin level
ovarian cancer
serum bilirubin
  • 27 Apr, 2022
  • 5 locations
A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)

This study, ELU- FRα-1, is focused on adult subjects who have advanced, recurrent or refractory folate receptor alpha (FRα) overexpressing tumors considered to be topoisomerase 1 inhibitor-sensitive based on scientific literature, and, in the opinion of the Investigator, have no other meaningful life-prolonging therapy options available. ELU001 is a new …

measurable disease
gastric cancer
triple negative breast cancer
lung cancer
ovarian cancer
  • 10 May, 2022
  • 7 locations
Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation

The FDA approved targeted agent tazemetostat inhibits EZH2 and induces durable tumor responses in patients with B-cell non-Hodgkin's lymphoma and epithelioid sarcomas. Responses have also been demonstrated in INI1 and SMARCA4 negative solid tumors patients. Since EZH2 plays a critical role in driving the biology of ARID1A mutated malignancies, we …

  • 21 Mar, 2022
  • 1 location
Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease

This study is being done to find out how often endometrial cancer recurs after the standard treatment as well as how often the standard treatment results in a lymphedema.

endometrioid carcinoma
  • 28 Feb, 2022
  • 11 locations
Artificial inTelligence in eNdometriosis-related ovArian Cancer and Precision Surgery in eNdometriosis-related ovArian Cancer

, including clear cell (CCC) endometrioid carcinoma which are both called "EMS-related ovarian carcinoma (EROC)". To date, it remains unclear why benign EMS causes malignant transformation. This multi-step

  • 24 Dec, 2021
  • 1 location